Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1649 1651 1674 1675
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18230480 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Non-Final OA | The Regents of the University of California |
| 17537308 | METHODS OF DETERMINING PATIENT POPULATIONS AMENABLE TO IMMUNOMODULATORY TREATMENT OF CANCER | Final Rejection | The Regents of the University of California |
| 19283716 | AFFINITY MATURED ANTI-OX40 ANTIBODIES AND USE THEREOF | Non-Final OA | Ichnos Sciences SA |
| 17758913 | COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND GAMMA SECRETASE INHIBITORS | Final Rejection | SpringWorks Therapeutics, Inc. |
| 18487767 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AUTOIMMUNE INDUCED CARDIAC LONG QT SYNDROME | Non-Final OA | New York University |
| 18343689 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Non-Final OA | Janssen Pharmaceutica NV |
| 18301803 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN | Non-Final OA | Neuracle Science Co., Ltd. |
| 18278188 | ANTI-CLEAVED HISTONE H3 MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES NEUTROPHIL EXTRACELLULAR TRAPS | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18013231 | ANTI-CD70 ANTIBODY AND APPLICATION THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18570834 | SYSTEMS AND METHODS FOR MONITORING AND TREATING STROKE | Non-Final OA | Arizona Board of Regents on Behalf of the Univerity of Arizona |
| 18473057 | ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES | Final Rejection | TeneoBio, Inc. |
| 18261419 | USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER'S DISEASE | Non-Final OA | Biohaven Therapeutics Ltd. |
| 18314956 | TREATMENT OF TAUOPATHIES | Non-Final OA | TauC3 Biologics Limited |
| 18176972 | CD38 PROTEIN ANTIBODY AND APPLICATION THEREOF | Non-Final OA | SUMGEN MAB (BEIJING) BIOTECH CO., LTD. |
| 18164521 | INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE | Non-Final OA | Bioverativ USA Inc. |
| 17769706 | DIABETES THERAPY TARGETING ABNORMAL STEM CELLS | Non-Final OA | Biozipcode, Inc. |
| 17769710 | THERAPY FOR DIABETES USING STEM CELL MIGRATION AGENT | Non-Final OA | Biozipcode, Inc. |
| 17778665 | BBB-SHUTTLING-VNARS CONJUGATED TO NEUROTROPHIC AGONIST ANTIBODIES TO TREAT NEURODEGENERATIVE DISEASES AND CONDITIONS | Non-Final OA | OSSIANIX, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy